Quantcast

Latest Clinical research Stories

2014-09-30 23:04:46

MarketOptimizer.org adds “Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. Dallas, Texas (PRWEB) October 01, 2014 Clinical trial report, “Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014″ provides data on the Idiopathic (Essential) Hypertension clinical trial scenario. This report provides...

2014-09-30 23:03:49

MarketOptimizer.org adds “Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Occlusive Arterial Disease (OAD). Dallas, Texas (PRWEB) October 01, 2014 Clinical trial report, “Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2014″ provides data on the Occlusive Arterial Disease (OAD) clinical trial scenario. This report provides elemental...

2014-09-30 20:23:13

OTTAWA, Sept. 30, 2014 /CNW/ - Protecting the health and safety of Canadians is our government's highest priority. Our expectation is that Health Canada uses the appropriate powers and tools at its disposal to help ensure that the drugs Canadians need meet the highest safety and quality standards. To that end, Health Canada has taken decisive action today to stop the import into Canada of all drug products from three plants in India. They are: -- Apotex Pharmachem India Pvt Ltd --...

2014-09-30 20:23:04

? Risk-Based Monitoring Solution Recognized at SCDM Annual Conference ? NEWTOWN, Pa., Sept. 30, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of outsourced clinical trial services and eClinical Solutions, today announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award, presented as part of SCDM's 2014 annual...

2014-09-30 16:28:07

Awards include targeted studies on effectiveness of transitional care services and obesity treatment WASHINGTON, Sept. 30, 2014 /PRNewswire-USNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved 46 new proposals, totaling nearly $102 million, to fund a wide range of patient-centered clinical comparative clinical effectiveness research (CER) projects. The new awards include support for studies focused on two high-impact topics --...

2014-09-30 16:28:04

Growth Capital Allows Alimera to Fulfill Its Milestone Obligation Triggered by FDA Approval of ILUVIEN® ATLANTA, Sept. 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). The payment is the second...

2014-09-30 12:30:55

DENVER, Sept. 30, 2014 /PRNewswire/ -- According to their CEO, Rob Bohacs - "the world of cancer clinical trials is going through a complete transformation with highly targeted biomarker clinical trials and the work of the current clinical trial management process isn't configured to accommodate these types of 'next generation' clinical trials, which will ultimately drive the prescription cancer drugs of tomorrow." The company has been recognized by the National Cancer Institute as...

2014-09-30 12:30:18

LAVAL, Quebec, Sept. 30, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the company's Bridgewater, New Jersey location received a Warning Letter from the U.S. Food and Drug Administration (FDA) relating to an inspection in June 2014 of the Company's records with regards to Sculptra Aesthetic injectable, which was divested to Galderma S.A. in July 2014. The Warning Letter pertains to the management of Valeant's contract...

2014-09-30 08:31:22

New Executive Brings Experience from Merck, Boehringer Ingelheim, and Proctor & Gamble PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for its growing portfolio of oncology and infectious disease DNA immunotherapies. As Inovio advances its lead program into...

2014-09-30 08:30:41

MUMBAI, September 30, 2014 /PRNewswire/ -- China's regulatory framework for in-vitro diagnostic reagents is undergoing earthshaking changes. The country's new leaders have recognized that the regulations for supervision and administration of in-vitro diagnostic reagents are far from perfect along with rapid population growth and thriving economy over the past 30 years. Chinese state council issued the latest "Regulations for the Supervision and Administration of Medical...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.